Financial Contrast: GoodRx (NASDAQ:GDRX) vs. Mercurity Fintech (NASDAQ:MFH)

GoodRx (NASDAQ:GDRX) and Mercurity Fintech (NASDAQ:MFH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Volatility & Risk

GoodRx has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Mercurity Fintech has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.

Insider & Institutional Ownership

63.8% of GoodRx shares are held by institutional investors. Comparatively, 30.8% of Mercurity Fintech shares are held by institutional investors. 1.4% of GoodRx shares are held by company insiders. Comparatively, 62.8% of Mercurity Fintech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for GoodRx and Mercurity Fintech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	1	8	10	0	2.47
Mercurity Fintech	0	0	0	0	N/A

GoodRx currently has a consensus target price of $8.78, suggesting a potential upside of 34.63%. Given GoodRx’s higher probable upside, analysts plainly believe GoodRx is more favorable than Mercurity Fintech.

Profitability

This table compares GoodRx and Mercurity Fintech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GoodRx	-1.18%	2.45%	1.25%
Mercurity Fintech	N/A	N/A	N/A

Earnings & Valuation

This table compares GoodRx and Mercurity Fintech’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$750.27 million	3.43	-$8.87 million	($0.02)	-325.84
Mercurity Fintech	$326,591.00	179.58	-$5.64 million	N/A	N/A

Mercurity Fintech has lower revenue, but higher earnings than GoodRx.

Summary

GoodRx beats Mercurity Fintech on 6 of the 11 factors compared between the two stocks.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

About Mercurity Fintech

Mercurity Fintech Holding Inc. operates as a fintech company powered by blockchain. The company provides digital asset trading infrastructure solutions based on internet and blockchain technologies for cryptocurrency traders; and asset digitalization platform, which offers blockchain-based digitalization solutions for traditional assets, such as fiat currencies, bonds, and precious metals. It also offers cryptocurrency mining services that provides computing power to the mining pool; and digital consultation services, such as digital payment solutions, asset management, and online and traditional brokerage services. The company was formerly known as JMU Limited and changed its name to Mercurity Fintech Holding Inc. in April 2020. Mercurity Fintech Holding Inc. was incorporated in 2011 and is headquartered in New York, New York.